• European Commission Approves Bavencio as First Immunotherapy for Adult Metastatic Merkel Cell Carcinoma
  • Opdivo, HPV Cancer Vaccine Combo Improves Response Rates in Oropharyngeal Cancer Patients
  • Tafinlar-Mekinist Combo is Highly Effective Adjuvant Therapy for Melanoma, Researchers Say
  • Keytruda Better than Standard Treatment for Advanced Head and Neck Cancer, Keynote-040 Study Shows
  • X4P-001 and Inlyta Combo Shows Promise Against Kidney Cancer, Trial Indicates
  • Imfinzi Reduces Risk of Disease Progression in Advanced NSCLC Patients, PACIFIC Trial Shows
  • Updated Phase 3 Trial Results Continue to Favor Keytruda as Second-Line Treatment for Bladder Cancer
  • Rocapuldencel-T Improves Survival in Renal Cell Carcinoma Patients, Phase 3 Trial Suggests
  • Immuno-oncology Becoming Established as Fifth Pillar of Cancer Therapy, Analysts Say
  • Experts Discuss Role of Cancer Immunotherapy at Bristol-Myers Presentation, Panel Discussion
  • Opdivo and Yervoy Combo Boosts Mesothelioma Survival, Phase 2 Clinical Trial Shows
  • Ionis’ Antisense Therapy Shows Promising Results when Combined with Imfinzi in Head and Neck Cancers